Trial Profile
A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients With Chemosensitive Advanced Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PIN
- 22 Jul 2020 This trial has been completed in United kingdom as per European clinical trail database record ( global end of the trial 2019-02-22 )
- 31 May 2020 Primary endpoint (Progression-free survival) has not been met, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology